SV2A

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Synaptic vesicle glycoprotein 2A
Identifiers
Symbols SV2A ; SV2
External IDs OMIM185860 MGI1927139 HomoloGene32237 ChEMBL: 1998 GeneCards: SV2A Gene
RNA expression pattern
PBB GE SV2A 203069 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 9900 64051
Ensembl ENSG00000159164 ENSMUSG00000038486
UniProt Q7L0J3 Q9JIS5
RefSeq (mRNA) NM_014849 NM_022030
RefSeq (protein) NP_055664 NP_071313
Location (UCSC) Chr 1:
149.87 – 149.89 Mb
Chr 3:
96.18 – 96.2 Mb
PubMed search [1] [2]

Synaptic vesicle glycoprotein 2A is a ubiquitous synaptic vesicle protein that in humans is encoded by the SV2A gene.[1][2][3] The protein is targeted by the anti-epileptic drug (AED) levetiracetam.[4]


References[edit]

  1. ^ Bajjalieh SM, Peterson K, Linial M, Scheller RH (Apr 1993). "Brain contains two forms of synaptic vesicle protein 2". Proc Natl Acad Sci U S A 90 (6): 2150–4. doi:10.1073/pnas.90.6.2150. PMC 46043. PMID 7681585. 
  2. ^ Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, Peterson MR, Scheller RH, Chavkin C, Bajjalieh SM (Jan 2000). "Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A)". Proc Natl Acad Sci U S A 96 (26): 15268–73. doi:10.1073/pnas.96.26.15268. PMC 24809. PMID 10611374. 
  3. ^ "Entrez Gene: SV2A synaptic vesicle glycoprotein 2A". 
  4. ^ Ulloa CM, Towfigh A, Safdieh J (2009). "Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures". Neuropsychiatr Dis Treat 5: 467–76. doi:10.2147/ndt.s4844. PMC 2747386. PMID 19777068. 

Further reading[edit]